US Fertility has teamed up with Alife Health to introduce AI-powered embryo imaging and reporting in their nationwide network of fertility practices. This collaboration will offer patients personalized IVF laboratory summary reports, complete with embryo images, grading, clinical significance, and next steps.
Richard Jennings, CEO of US Fertility, expressed excitement about the partnership, emphasizing that Alife’s technology will revolutionize the delivery of IVF services, enhancing patient engagement and setting a new industry standard. Alife’s Embryo Assist tool will automate the process of embryo grading, allowing for efficient data organization and reducing manual documentation time.
Dr. Kate Devine, Medical Director of US Fertility, highlighted the benefits of integrating AI through Alife’s reporting system, emphasizing the improvements in operational efficiency and patient experience. Melissa Teran, CEO of Alife, praised the partnership as a gamechanger for the fertility industry, emphasizing the confidence US Fertility has placed in their AI approach to IVF.
The partnership between US Fertility and Alife covers over 100 clinics and 32 IVF laboratories across the United States, benefiting tens of thousands of patients annually. This collaboration showcases the significant role that AI is set to play in the future of fertility treatments, enhancing clinical workflow, patient care, and overall experience.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
